MOTS-c
Mitochondrial · By Preptide Pro editorial team · Last updated
MOTS-c is a mitochondrial peptide, and it is not FDA-approved. A short peptide encoded in mitochondrial DNA. Studied in lab and animal models of metabolism and exercise biology.
Not FDA-approvedChemistry (PubChem)
| PubChem CID | 146675088 |
|---|---|
| CAS number | 1627580-64-6 |
| Molecular formula | C101H152N28O22S2 |
| Molecular weight | 2174.6 g/mol |
| Other names | Mots-c, UNII-A5CV6JFB78, MOTS-c (human) (trifluoroacetate salt), H-MRWQEMGYIFYPRKLR-OH, orb2279120, orb3032863, Mitochondria-derived peptide mots-c, EX-A6267 |
Is MOTS-c FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on MOTS-c?
PubMed lists 265 records for “MOTS-c”, of which 5 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Mitochondria-derived peptide hydrogel augments mitochondrial transplantation for promoting cardiac repair via macrophage metabolic reprogramming. | Bioact Mater | 2027 Jan |
| MOTS-c is associated with oxidative stress and arterial stiffness in peritoneal dialysis patients: a pilot study. | Int Urol Nephrol | 2026 Nov |
| Mots-c attenuates diabetic nephropathy by downregulating LARS1 to promote lipophagy and suppress tubular senescence. | Biochem Pharmacol | 2026 Oct 23 |
| Mitochondrial-derived peptides (MDPs) activated by physical exercise as therapeutic targets for metabolic disorders: A systematic review. | Physiol Int | 2026 Oct 16 |
| MOTS-c in sepsis-induced cardiomyopathy: Mechanisms and translational potential. | Eur J Pharmacol | 2026 Oct 15 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.